Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25019679 | 0.76 | TSHR (0.31) | — | |
| SCHEMBL359980 | 0.76 | TSHR (0.31) | — | |
| SCHEMBL28327923 | 0.76 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL11104417 | 0.74 | DPP4 (0.36) | DPP4 | |
| Ammonia Solution, Strong SCHEMBL3675032 | 0.74 | — | — | |
| Valine SCHEMBL1761381 | 0.74 | SLC7A5 (0.71) | SLC7A5SLC1A3SLC1A2SLC1A1DPP8 | |
| SCHEMBL5218767 | 0.74 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL19812415 | 0.74 | TP53 (0.33) | — | |
| SCHEMBL678145 | 0.74 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1CASR | |
| SCHEMBL3449733 | 0.74 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854792-B1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-12-26 | — | — | EP | disclosed |
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1854792-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030195-A1 | 1-(2H)-ISOQUINOLONE DERIVATIVE | NQO1, NR5A1, SRD5A1 | SLC7A5 405/4885SLC1A3 3634/4885SLC1A2 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.